依那普利或厄贝沙坦联合氢氯噻嗪治疗中重度高血压的临床疗效及安全性评价  

Clinical efficacy and safety evaluation of enalapril or irbesartan combined with hydrochlorothiazide in the treatment of medium or severe hypertension

作　　者：宋海宁[1] 赖海燕[1] 李茜[1] 

机构地区：[1]成都市第三人民医院药剂科,成都610014

出　　处：《中国临床药理学杂志》2015年第16期1563-1565,共3页The Chinese Journal of Clinical Pharmacology

基　　金：国家科技支撑计划基金资助项目(2013BA06B04)

摘　　要：目的评价依那普利或厄贝沙坦联合氢氯噻嗪治疗中重度高血压的临床疗效及安全性。方法将69例患者随机分为对照组34例和试验组35例。对照组予以口服氢氯噻嗪12.5 mg+依那普利10 mg,每日2次;试验组予以口服氢氯噻嗪12.5 mg+厄贝沙坦150 mg,每日2次。2组患者疗程均为2个月。治疗后,比较2组的临床疗效、血清肌酸酐、尿酸、血钾水平以及不良反应发生率。结果治疗后,2组患者血压均明显下降,对照组与试验组的总有效率分别为88.24%和88.57%(P>0.05)。2组患者治疗前后血清肌酸酐、尿酸及血钾无明显变化(P>0.05)。对照组出现4例夜间干咳,发生率为11.67%,试验组无患者发生夜间干咳,差异无统计学意义(P>0.05)。结论依那普利或厄贝沙坦联合氢氯噻嗪治疗中重度高血压的临床疗效相当,但贝沙坦联合氢氯噻嗪无明显夜间干咳。Objective To evaluate the clinical efficacy and safety of enalapril or irbesartan combined with hydrochlorothiazide in the treatment of medium or severe hypertension. Methods Sixty- nine patients with moderate to severe essential hypertension were randomly divided into control group（ n = 34） with enalapril 10 mg ＋ hydrochlorothiazide 12. 5mg orally bid and treatment group（ n = 35） with irbesartan 50 mg ＋hydrochlorothiazide 12. 5 mg orally bid with 2 months. After treatment,the clinical efficacy,serum level of creatinine,acidum uricum and potassium and the ratio of adverse event were compared between the two groups.Results After 2 months treatment,the blood pressure was significant decreased in control and treatment groups. The clinical efficacy were88. 24% and 88. 57% with not statistical difference（ P〉0. 05）. The serum level of creatinine,acidum uricum and potassium had no obvious difference before and after the treatment in the two groups（ P〉0. 05）. Four cases of cough were observed in the control group and the treatment group,respectively,without statistical difference（ P〉0. 05）. Conclusion There was no clinical efficacy difference for enalapril or irbesartan combined with hydrochlorothiazide in the treatment of medium or severe hypertension. But irbesartan combined with hydrochlorothiazide had less cough adverse event.

关 键 词：依那普利 厄贝沙坦 氢氯噻嗪 临床疗效 安全性 

分 类 号：R544.1[医药卫生—心血管疾病] R972.4[医药卫生—内科学]